- Record: found
- Abstract: not found
- Article: not found
Ibrutinib for relapsed mantle cell lymphoma after standard first line therapy and ASCT is efficacious but does not overcome the impact of POD24 ‐ a retrospective study from the LWP‐EBMT
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.